VEGFA and neoplasm: Targeting AGTR1 could significantly inhibit tumor growth via inactivation of the phosphorylation of PLC β3, which could disrupt tumor angiogenesis by reducing the VEGF production, thus inhibiting endothelial cell survival (72).